Orange County Retina Med Group

Santa Ana, California 92705-6504

1 studies enrolling now · 12 studies all time

What they study most

Choroidal Neovascularization, Diabetic Macular Edema, Geographic Atrophy, Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration

Studies at this site

• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) — Recruiting now
• Extension Study for the Port Delivery System With Ranibizumab (Portal) — Recruiting now
• Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration — Running, not enrolling
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema — Completed
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) — Completed
• A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration — Completed
• Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration — Completed
• A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) — Completed
• A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) — Stopped early